Carlyle and SK Capital Acquire bluebird bio

Bertram Capital Partners With Bluebird Founders in Recapitalization of The Bluebird Group (H.I.G. Sells Minority Stake)

June 16, 2026

Data & Analytics

H.I.G. Capital sold its minority stake in The Bluebird Group as the company’s founders and Bertram Capital recapitalized the business. The companies did not disclose financial terms. Bluebird is an omnichannel, data and analytics-driven commerce services partner headquartered in Minneapolis, Minnesota.

Blue Bird Acquires Girardin’s Stake in Micro Bird Joint Venture

February 17, 2026

Manufacturing

Blue Bird Corporation signed an agreement to acquire Girardin Group’s stake in the 50/50 Micro Bird joint venture, taking full ownership of the business. The transaction is valued at approximately $200 million and is expected to close in the first half of calendar year 2026, pending regulatory approvals and other closing conditions.

cbdMD Acquires Substantially All Assets of Bluebird Botanicals

January 29, 2026

Consumer Products

cbdMD, Inc. (NYSE American: YCBD) acquired substantially all assets of Bluebird Botanicals in early January 2026 to integrate Bluebird's regulatory science, safety and IP assets into cbdMD's clinical and toxicology platform. The deal strengthens cbdMD's regulatory-compliance and GRAS capabilities for both broad-spectrum and full-spectrum cannabinoid formulations and is expected to contribute to revenue growth and expanded product safety dossiers.

Sanofi to Acquire Blueprint Medicines to Expand Rare Immunology Pipeline

June 2, 2025

Pharmaceuticals

Sanofi and Blueprint Medicines entered into an agreement under which Sanofi will acquire Blueprint via a cash tender offer and subsequent merger. The deal values Blueprint at $129.00 per share in cash (approximately $9.1 billion equity value), with additional potential milestone payments tied to BLU-808 via a contingent value right.

Bristol Myers Squibb to Acquire 2seventy bio in $5.00/share All-Cash Deal

March 25, 2025

Healthcare Services

2seventy bio entered into a definitive merger agreement to be acquired by Bristol Myers Squibb (BMS) for $5.00 per share in an all-cash transaction. The deal is expected to close in the second quarter of 2025, following a tender offer and a second-step merger.

H.I.G. Capital Makes Equity Investment in The Bluebird Group

August 9, 2021

Marketing & Advertising

An affiliate of H.I.G. Capital has made an equity investment in The Bluebird Group, a Minneapolis-based retail services and consulting firm. The investment will support Bluebird's expansion and development of next-generation digital insights and analytics to enhance services for consumer brands.